Search Results for "Alnylam"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Patisiran: Premedications
Standard response letter on patisiran and premedications during the APOLLO, Global OLE, and APOLLO-B studies.
Standard response letter on patisiran and premedications during the APOLLO, Global OLE, and APOLLO-B studies.
APOLLO Post-Hoc Analysis by Baseline Polyneuropathy Severity
A post-hoc analysis of the APOLLO trial was performed to evaluate the use of patisiran compared to placebo by baseline NIS quartile in patients with the the polyneuropathy of hATTR. This infographic summarizes the post-hoc analysis results, which were published in the journal Amyloid.
A post-hoc analysis of the APOLLO trial was performed to evaluate the use of patisiran compared to placebo by baseline NIS quartile in patients with the the polyneuropathy of hATTR. This infographic summarizes the post-hoc analysis results, which were published in the journal Amyloid.
